Amitoj Gill, MD

Hematology Oncology
Gender: Male
4.8 of 5 (247 Ratings)
Accepting New Patients

Practice Locations

A:
Baptist Health Medical Group Hematology & Oncology
2210 Green Valley Road, Suite 1
New Albany, IN 47150
812-945-4000 812-941-5714
B:
Baptist Health Medical Group Hematology & Oncology
941 West McClain Avenue, Suite C
Scottsburg, IN 47170
812-945-4000 812-752-2555
C:
Baptist Health Medical Group Hematology & Oncology
101 Hospital Boulevard
Jeffersonville, IN 47130
812-945-4000 812-941-5714

Education

ECFMG

Educational Commission for Foreign Medical Graduates

Residency

Johns Hopkins Univ School of Medicine

Fellowship

University of Louisville

Board Certifications

Hematology

American Board of Internal Medicine

Medical Oncology

American Board of Internal Medicine

Hospital Affiliations

  • Baptist Health LaGrange
  • Baptist Health Floyd

Philosophy of Care

Baptist Health Medical Group is a comprehensive, multispecialty network of physicians and advanced practice clinicians. Our providers are committed to providing compassionate, patient-centered care and strive to treat our patients the way we would want to be treated, every time, at every Baptist Health location.

Reviews

Patient Experience Ratings

The Patient Satisfaction Rating is an average of all responses to the care provider related questions shown below from our survey. Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.

Overall Rating
4.8 out of 5 (247 Ratings)
Review Categories
Patient Comments

Research

  • Carcinoma, Non-Small-Cell Lung

    Pacific 4: A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab with Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients with unresected Stage I/II, lymph-node negative NSCLC

    Trial Details
  • Early Cancer Detection (SIRB-23-0050)

    Adela CAMPERR: cfMeDIP-seq Assay Multicenter Prospective Observational Validation for Early Cancer Detection, Minimal Residual Disease, and Relapse (CAMPERR)

    Trial Details
  • Hematology

    READY 1: A Phase 3, Randomized, Double-Blind, Active and Placebo-Controlled Study on the use of CUSA-081 for Dysfunctional Central Venous Access Devices (CVADs)

    Trial Details
  • Non-small Cell Lung Cancer (NSCLC)

    Pacific 9: A Phase III, double-blind, placebo-controlled, Randomized, Multicentre, International Study of Durvalumab Plus Oleclumab and Durvalumab Plus Monalizumab in Patients With Locally Advanced (Stage III), Unresectable Non-small Cell Lung Cancer (NSCLC) Who Have Not Progressed Following Definitive, Platinum-Based Concurrent Chemoradiation Therapy

    Trial Details